KEYTRUDA® + axitinibfor RCC: video on the latest update of KEYNOTE-426.

Watch this video discussing the updated results of the KEYNOTE-426 study: 27-month median follow-up analysis of the efficacy and safety of pembrolizumab+axitinibin RCC patients.

New BSMO guidelines for clear-cell Renal Cell Carcinoma

An update on the management of metastatic clear-cell renal cell carcinoma: the BSMO expert panel recommendations.

BE-KEY-00298 Date of last revision 10/2020